Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis

被引：0
作者：
Wanruchada Katchamart
Pongthorn Narongroeknawin
Ngamsiree Sukprasert
Wanwisa Chanapai
Ananya Srisomnuek
机构：
[1] Mahidol University,Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital
[2] Phramongkutklao Hospital and College of Medicine,Division of Rheumatology, Department of Medicine
[3] Mahidol University,Department of Medicine, Faculty of Medicine Siriraj Hospital
[4] Mahidol University,Division of Clinical Trials, Research Department, Faculty of Medicine Siriraj Hospital
来源：
Clinical Rheumatology | 2021年 / 40卷
关键词：
Compliance-Questionnaire-Rheumatology; Medication compliance; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1291 / 1298
页数：7
相关论文
共 50 条
  • [21] Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis
    Combe, Bernard
    JOINT BONE SPINE, 2006, 73 (06) : 587 - 590
  • [22] Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs
    Kim, Seoyoung C.
    Solomon, Daniel H.
    Liu, Jun
    Franklin, Jessica M.
    Glynn, Robert J.
    Schneeweiss, Sebastian
    AMERICAN JOURNAL OF MEDICINE, 2015, 128 (05) : 539.e7 - 539.e17
  • [23] Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Terabe, Kenya
    Takahashi, Nobunori
    Asai, Shuji
    Hirano, Yuji
    Kanayama, Yasuhide
    Yabe, Yuichiro
    Oguchi, Takeshi
    Fujibayashi, Takayoshi
    Ishikawa, Hisato
    Hanabayashi, Masahiro
    Hattori, Yosuke
    Suzuki, Mochihito
    Kishimoto, Kenji
    Ohashi, Yoshifumi
    Imaizumi, Takahiro
    Imagama, Shiro
    Kojima, Toshihisa
    MODERN RHEUMATOLOGY, 2023, 33 (02) : 292 - 301
  • [24] Disease-Modifying Antirheumatic Drugs Increase Serum Adiponectin Levels in Patients With Rheumatoid Arthritis
    Cansu, Baris
    Cansu, Dondu U.
    Kasifoglu, Timucin
    Gulbas, Zafer
    Korkmaz, Cengiz
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (01) : 14 - 17
  • [25] Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients
    Griffiths, RI
    Bar-Din, M
    MacLean, C
    Sullivan, EM
    Herbert, RJ
    Yelin, EH
    THERAPEUTIC APHERESIS, 2001, 5 (02): : 92 - 104
  • [26] Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
    Joo, Young Bin
    Jung, Seung Min
    Park, Yune-Jung
    Kim, Ki-Jo
    Park, Kyung-Su
    JOURNAL OF RHEUMATIC DISEASES, 2022, 29 (03): : 162 - 170
  • [27] Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA)
    Münster, T
    Furst, DE
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (06) : S29 - S36
  • [28] Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis
    Grijalva, Carlos G.
    Chung, Cecilia P.
    Arbogast, Patrick G.
    Stein, Charles M.
    Mitchel, Edward F., Jr.
    Griffin, Marie R.
    MEDICAL CARE, 2007, 45 (10) : S66 - S76
  • [29] Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis
    Neide Tomimura Costa
    Tatiana Mayumi Veiga Iriyoda
    Daniela Frizon Alfieri
    Andréa Name Colado Simão
    Isaias Dichi
    Inflammopharmacology, 2018, 26 : 1151 - 1164
  • [30] Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis
    Williams, HJ
    BRITISH JOURNAL OF RHEUMATOLOGY, 1995, 34 : 96 - 99
12345